Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Boosting progesterone may save IVF pregnancies

NCT ID NCT05555121

Disease control Sponsor: Clinique Ovo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving a higher dose of the progesterone supplement Endometrin to women with low blood levels on the day of embryo transfer can improve pregnancy rates and lower miscarriage risk. About 150 women aged 18-42 undergoing frozen embryo transfer will be split into groups based on their progesterone levels. The goal is to see if personalized dosing leads to better outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2022

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 42 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women 18-42 years of age * Normal uterine cavity (according to treating physician) * FET substituted cycle prescribed * First or second cycle of FET * Adequate endometrial pattern (triple layer) and thickness (\>7 mm) after adequate standard endometrial preparation in artificial cycle Exclusion Criteria: * Any uterine abnormalities confirmed by treating physician making participant unable to proceed with FET * Patients with personalized FET according to the endometrial receptivity assay tests * Previous allergic reactions to progesterone or any of the ingredients of Endometrin * Severe hepatic dysfunction or disease * Known or suspected breast cancer or genital tract cancer * Known active arterial or venous thromboembolism or severe thrombophlebitis or cerebro-vascular disease, or a history of these events * Diagnosed porphyria * Undiagnosed abnormal vaginal bleeding * Known missed abortion or ectopic pregnancy * Recurrent pregnancy loss excluding biochemical pregnancies * Hypersensitivity to Acetylsalicylic acid (ASA), salicylates, non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, antipyretics or other ingredients in the product or component of the container * Acute gastrointestinal ulcer, history of gastrointestinal ulcers and hemorrhagic diathesis * Active or severe renal disease, or congestive heart failure * History of asthma induced by salicylates or other NSAIDs * Use of methotrexate at doses of 15mg/week or more * Glucose-6-phosphate dehydrogenase (G6PD) deficiency

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Embryo implantation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Embryo implantation Fertility issues Frozen embryo transfer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinique Ovo

    Montreal, Quebec, H4P 2S4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.